Becton Dickinson and Co Depositary ETF News

Becton Dickinson and Co BDX reported Q1 FY22 revenues of $4.9 billion, down 6% Y/Y (-5.9% on a currency-neutral basis), better than the consensus of $4.76 billion. Get the Inside Access Traders Are U

Becton Dickinson (BDX) delivered earnings and revenue surprises of 27.27% and 4.65%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Becton, Dickinson and Company (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Becton, Dickinson and Co (NYSE: BDX) has acquired Cytognos, a unit of Vitro SA, a Spanish diagnostics company that develops, produces, and sells fully integrated reagents, hardware, and software pl

Becton Dickinson (BDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Beckton, Dickinson and Company is a Profitable Dividend Aristocrat that generates tons of cash.

Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic buyouts.

BD (BDX) collaborates with retail partners and distributors to make the BD Veritor At-Home COVID-19 Test widely accessible.

Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic deals.

Becton Dickinson & Co. BDX, +0.90% said Monday that the spinoff of its diabetes care business will be named "embecta." The previously announced spinoff, into an independent publicly traded company, is

Shares of Becton, Dickinson and Co. ( BDX , Financial) reported earnings results earlier this month that came in above Wall Street analysts' estimates. Covid-19 remains a tailwind to the company's bus

CNBC's Meg Tirrell joins 'Squawk Box' to report on the increased demand for Covid-19 tests ahead of the Thanksgiving holiday.

Becton, Dickinson Is A Strong Buy At $250

Qiagen N.V. (NYSE: QGEN) settled with Becton Dickinson & Co (NYSE: BDX) a patent infringement lawsuit related to Qiagen's NeuMoDx 96 and NeuMoDx 288 clinical PCR systems.